Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Hepatology. 2010 Jan;51(1):121-9. Nonalcoholic steatohepatitis (NASH) is a chronic progressive liver disease that is strongly associated with obesity. Currently, there is no approved therapy for NASH.
Preferences for colorectal cancer screening strategies: a discrete choice experiment.Hol L, de Bekker-Grob EW, van Dam L, Donkers B, Kuipers EJ, Habbema JD, Steyerberg EW, van Leerdam ME, Essink-Bot ML. Br J Cancer. 2010 Mar 2. [Epub ahead of print] Background:Guidelines underline the role of individual preferences in the selection of a screening test, as insufficient…
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Am J Gastroenterol. 2010 Jan;105(1):65-73. Epub 2009 Sep 15. OBJECTIVES: Recent treatment guidelines recommend two first-line therapies for Helicobacter pylori infection: proton pump inhibitor…
Meta-analysis: folic acid in the prevention of colorectal adenomas and the chemoprevention of colorectal cancer. Carroll C, Cooper K, Papaioannou D, Hind D, Tappenden P, Pilgrim H, Booth A. Aliment Pharmacol Ther. 2010 Jan 18. [Epub ahead of print] Summary: Background: Folic acid has been identified as a possible agent for the chemoprevention of colorectal cancer.
Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials.Wenzhen Y, Yumin L, Kehu Y, Bin M, Quanlin G, Donghai W, Lijuan Y. Scand J Gastroenterol. 2010 Mar 4. [Epub ahead of print] Abstract Background. Helicobacter pylori (H. pylori) infection and iron deficiency anemia are prevalent in disadvantaged populations worldwide. The benefit of H.…
Review article: omega-3 fatty acids – a promising novel therapy for non-alcoholic fatty liver disease.Masterton GS, Plevris JN, Hayes PC. Aliment Pharmacol Ther. 2009 Dec 30. [Epub ahead of print] Summary Background Non-alcoholic fatty liver disease (NAFLD) affects 10-35% of the adult population worldwide; there is no consensus on its treatment. Omega-3 fatty acids have proven…